# A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

> **NCT05595642** · PHASE3 · RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 1290 (estimated)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** Astegolimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05595642
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-29
- **Primary completion:** 2025-06-24
- **Final completion:** 2027-09-24
- **Target enrollment:** 1290 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05595642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05595642, "A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05595642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*